文献速递肝病消化内镜

基于机器学习的筛查高危食管静脉曲张评分系统的开发与验证

Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-01-29

研究利用洛杉矶3家医院238例肝硬化患者的 readily available 数据开发EVendo评分,并在109例前瞻性验证队列中验证,识别食管静脉曲张的AUROC为0.84(训练集)和0.82(验证集),识别需治疗静脉曲张的AUROC为0.74和0.75;评分低于3.90可使30.5%患者免于内镜,仅遗漏2.8%需治疗静脉曲张。

要点

  • EVendo评分基于INR、AST、血小板计数、尿素氮、血红蛋白和腹水,用于预测肝硬化患者食管静脉曲张及需治疗静脉曲张。
  • 训练集238例中识别食管静脉曲张的AUROC为0.84,验证集109例中为0.82。
  • 评分低于3.90可使30.5%患者免于内镜筛查,仅遗漏2.8%的需治疗静脉曲张。

核心结论

  • 基于 readily available 数据算法化开发的EVendo评分可用于预测肝硬化患者的食管静脉曲张和需治疗静脉曲张,该评分可能帮助低危患者避免不必要的内镜筛查。

研究设计与样本

  • 训练队列:2016年1月至2017年12月洛杉矶3家医院238例接受筛查性内镜的肝硬化患者,回顾性收集数据。
  • 验证队列:2018年1月至2018年12月同一医疗中心109例接受筛查性内镜的前瞻性研究。
  • 使用随机森林算法识别与食管静脉曲张及需治疗静脉曲张显著相关的因素并计算AUROC。

主要发现

  • EVendo评分识别食管静脉曲张的AUROC:训练集0.84,验证集0.82,Child-Turcotte-Pugh A级肝硬化患者(n=235)中0.81。
  • EVendo评分识别需治疗静脉曲张的AUROC:训练集0.74,验证集0.75,Child-Turcotte-Pugh A级肝硬化患者中0.75。
  • EVendo评分低于3.90可使30.5%患者免于内镜,仅遗漏2.8%的需治疗静脉曲张。
  • 同一截断值可使40.0%的Child-Turcotte-Pugh A级肝硬化患者免于内镜,仅遗漏1.1%的需治疗静脉曲张。

关键数值与推荐

  • EVendo评分基于INR、AST水平、血小板计数、尿素氮、血红蛋白和腹水存在与否构建。
  • 识别需治疗静脉曲张的截断值为EVendo评分低于3.90。

临床怎么用

  • 作者认为EVendo评分可帮助低危患者避免不必要的内镜筛查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Many patients with cirrhosis who undergo esophagogastroduodenoscopy (EGD) screening for esophageal varices (EVs) are found to have no or only small EVs. Endoscopic screening for EVs is therefore a potentially deferrable procedure that increases patient risk and healthcare cost. We developed and validated a scoring system, based on readily-available data, to reliably identify patients with EVs that need treatment. METHODS: We collected data from 238 patients with cirrhosis undergoing screening EGD from January 2016 through December 2017 at 3 separate hospitals in Los Angeles (training cohort). We abstracted data on patient sex, age, race/ethnicity, platelet counts, and levels of hemoglobin, serum sodium, aspartate aminotransferase, alanine aminotransferase, total bilirubin, international normalized ratio, albumin, urea nitrogen, and creatinine. We also included etiology of cirrhosis, presence of ascites, and presence of hepatic encephalopathy. We used a random forest algorithm to identify factors significantly associated with the presence of EVs and varices needing treatment (VNT) and calculated area under the receiver operating characteristic curve (AUROC). We called the resulting formula the EVendo score. We tested the accuracy of EVendo in a prospective study of 109 patients undergoing screening EGDs at the same medical centers from January 2018 through December 2018 (validation cohort). RESULTS: We developed an algorithm that identified patients with EVs and VNT based on international normalized ratio, level of aspartate aminotransferase, platelet counts, urea nitrogen, hemoglobin, and presence of ascites. The EVendo score identified patients with EVs in the training set with an AUROC of 0.84, patients with EVs in the validation set with and AUROC of 0.82, and EVs in patients with cirrhosis Child-Turcotte-Pugh class A (n = 235) with an AUROC of 0.81. The score identified patients with VNT in the training set with an AUROC of 0.74, VNT in the validation set with and AUROC of 0.75, and VNT in patients with cirrhosis Child-Turcotte-Pugh class A with and AUROC of 0.75. An EVendo score below 3.90 would have spared 30.5% patients from EGDs, missing only 2.8% of VNT. The same cutoff would have spared 40.0% of patients with Child-Turcotte-Pugh class A cirrhosis from EGDs, missing only 1.1% of VNT. CONCLUSIONS: We algorithmically developed a formula, called the EVendo score, that can be used to predict EVs and VNT based on readily available data in patients with cirrhosis. This score could help patients at low risk for VNT avoid unnecessary EGDs.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Dong TS, Kalani A, Aby ES, et al. Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices. Clin Gastroenterol Hepatol. 2019. PMID: 30708109. doi:10.1016/j.cgh.2019.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。